On Monday, July 30, Intellipharmaceuticals settled “patent infringement claims brought by AstraZeneca Pharmaceuticals LP over plans to market a generic version of anti-psychotic drug Seroquel XR®, agreeing to delay the launch of its version and admit the legitimacy of AstraZeneca’s Seroquel® patents.” AstraZeneca is represented by Finnegan in this matter.
